CALR and fibrosarcoma: Of note, (R)-crizotinib was more efficient than its enantiomer (S)-crizotinib in inducing CALR-RFP redistribution and pyknosis in U2OS cells (Fig. 1c, d), as well as in mouse fibrosarcoma MCA205 and lung adenocarcinoma TC1 cells (Fig. 1d).